Abstract: A biliquid foam includes from 10% to 98% by weight of a non-polar liquid other than a fuel and from 2 to 88% by weight of a continuous phase polar liquid comprising a C1-C4 alcohol, a liquid polyethylene glycol, ethylene glycol or propylene glycol, or mixtures thereof, in an amount of at least 65% by weight, relative to the weight of the continuous phase, wherein the biliquid foam is stabilized with an amount of from 0.05% to 2% by weight based on the total formulation of a surfactant which is selected from castor oil/poly(alkylene glycol) adducts containing from 20 to 50 alkoxy groups, a C8-C24 fatty acid or hydrogenated castor oil/poly(alkylene glycol) adducts containing from 20 to 60 alkoxy groups, or mixtures thereof.

Abstract: A biliquid foam comprising from 10% to 98% by weight of a non-polar liquid other than a fuel and from 2 to 88% by weight of a continuous phase polar liquid comprising a C1-C4 alcohol, a liquid polyethylene glycol, ethylene glycol or propylene glycol, or mixtures thereof, in an amount of at least 65% by weight, relative to the weight of the continuous phase, wherein the biliquid foam is stabilized with an amount of from 0.05% to 2% by weight based on the total formulation of a surfactant which is selected from castor oil/poly(alkylene glycol) adducts containing from 20 to 50 alkoxy groups, a C8-C24 fatty acid or hydrogenated castor oil/poly(alkylene glycol) adducts containing from 20 to 60 alkoxy groups, or mixtures thereof. A stable dispersion having a content of at least 65% by weight with regard to C1-C4 alcohol, liquid polyethylene glycol, ethylene glycol or propylene glycol which dispersion comprises from 1-80% by weight of a biliquid foam and from 99-20% by weight of an aqueous gel.

Abstract: An oral drug delivery system which comprises a biliquid foam comprising: from 1 to 20% by weight of a continuous hydrophilic phase, from 70 to 98% by weight of a pharmaceutically acceptable oil which forms a discontinuous phase, the said pharmaceutically acceptable oil having dissolved or dispersed therein a poorly water-soluble drug in an amount of from 0.1 to 20% by weight and the biliquid foam including therein from 0.5 to 10% by weight of a surfactant to enable the formation of a stable biliquid foam, all percentages being based upon the total weight of the formulation.

Abstract: A fuel composition which comprises a biliquid foam consisting of from 10% to 97.5% by weight of non-coalescing droplets of a non-polar liquid comprising a petroleum derivative, paraffin or a liquid halogenated hydrocarbon and from 2 to 87% by weight of a continuous phase polar liquid comprising a C1-C3 alcohol, a C4 alcohol containing at least two hydroxy groups, or ethylene glycol, or mixtures thereof, in an amount of from 60% to 100% by weight thereof, wherein the biliquid foam is stabilized with an amount of from 0.5 to 3.0% by weight based on the total formulation of a surfactant which is selected from castor oil/poly(alkylene glycol) adducts containing from 20 to 50 alkoxy groups, or hydrogenated castor oil/poly(alkylene glycol) adducts containing from 20 to 60 alkoxy groups, or mixtures thereof.

Abstract: A method for the preparation of a biliquid foam which does not rely upon the initial formation of a gas foam, in which a stirrer having a single or a multiplicity of blades is used, the stirrer being operated in a manner such that at least one part of the stirrer mechanism breaks the interface between the continuous polar phase used to form the biliquid foam and the air, the non-polar phase being added dropwise at least initially whilst stirring the continuous polar phase and the rate of addition of the non-polar phase being controlled so that a biliquid foam composition is formed.